Besudil mesylate tablets dosage guide

Besudil mesylate tablets are an innovative kinase inhibitor designed for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) who have not responded to at least two systemic treatments. By blocking the ROCK2 pathway, the drug helps rebalance the immune system of patients with chronic GVHD, effectively reducing swelling and scar tissue accumulation, thereby improving patients' quality of life.

The recommended dose of besudil mesylate is200 mg taken orally once daily and continued until chronic GVHD progresses to the point where new systemic therapy is required. To ensure the effectiveness of the medication and patient safety, here are some key dosing guidelines:

1. Swallow the whole tablet: When taking Besudil mesylate tablets, patients should swallow the tablets whole. Do not cut, crush or chew the tablets. This can ensure the complete release and absorption of the drug and avoid affecting the efficacy of the drug.

2. Take it regularly: It is recommended to take Besudil mesylate tablets at about the same time every day with meals. This helps maintain a stable concentration of the drug in the body.

3. Handling of missed doses: If a patient misses a dose, do not take an additional dose to make up for it. Missing a dose usually does not significantly affect treatment, but taking an overdose may increase unnecessary risks.

4. Precautions for patients with renal impairment: The treatment of Besudil Mesylate Tablets has not been studied in patients with severe renal impairment. Therefore, for such patients, doctors should carefully evaluate the risks and potential benefits before starting treatment to ensure the safety of the medication.

5. Drug interactions: When besudil mesylate tablets are used together with strongCYP3A inducers or proton pump inhibitors, the dose may need to be increased to 200 mg twice daily. At the same time, concurrent use with certain P-gp, OATP1B1, BCRP, and UGT1A1 substrates should be avoided, as even the smallest concentration changes may lead to severe toxic reactions. If coadministration cannot be avoided, adjust the substrate dosage according to the respective prescribing information.

6. Use in patients with hepatic impairment: Besudil mesylate tablets should be avoided in patients with moderate or severe hepatic impairment (Child-Pugh B or C) but without hepatic GVHD. For patients with mild hepatic impairment, it is not recommended to adjust the dosage when using Besudil Mesylate Tablets.

In short, patients should strictly follow the doctor's instructions when taking Besudil Mesylate Tablets to ensure the correctness and safety of the medication. At the same time, communicate with doctors regularly and adjust treatment plans in a timely manner to ensure safe and effective medication.

Reference materials:https://www.drugs.com/pro/rezurock.html